Triumvira Immunologics to Participate in Four Upcoming Healthcare Investor Conferences in October and November 2022
AUSTIN, Texas, & HAMILTON, Ontario--(BUSINESS WIRE)-- Triumvira Immunologics, Inc. (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that Senior Management will participate in four upcoming healthcare investor conferences.
- Oppenheimer Private Company Showcase: The Next Wave: presentation at 2:35 pm PT on Tuesday, October 18th and available for investor meetings
- Bank of America Healthcare Life Sciences Private Company Conference: available for in-person investor meetings on Thursday, October 20th
- Wells Fargo Private Biotech Symposium: available for virtual investor meetings on Wednesday, November 2nd
- Stifel 2022 Healthcare Conference: presentation on Wednesday, November 16th at 9:10 am ET and available for investor meetings
About Triumvira Immunologics
Triumvira is a clinical-stage company developing a best-in-class, rationally designed cell therapy platform based on its proprietary T cell Antigen Coupler (TAC) technology. Its lead candidate, TAC01-HER2, is being evaluated in an ongoing Phase 1/2 trial for HER2-positive solid tumors with positive initial safety and efficacy data to-date. Triumvira’s pipeline includes other compelling pre-clinical solid tumor programs targeting Claudin 18.2, GUCY2C and GPC3, among others, with anticipated IND filings over the next few years. Supporting the pipeline has been an industrialized, drug-like, approach to manufacturing, including the first-mover adoption of the Lonza Cocoon® Platform that has yielded high quality product and a very high manufacturing success rate at a lower cost compared to other autologous approaches. Building on the proof-of-concept of its clinical-stage autologous TAC01-HER2 program, Triumvira is continuing to develop and advance its gamma delta allogeneic pipeline with IND filings anticipated over the next three years.
Source: Triumvira Immunologics